JAK2 and breast carcinoma: In addition, azilsartan treatment was shown to reduce the expression of NF-κB mRNA and IL-6, JAK2, and STAT3 proteins, thus promoting many cellular pathways in malignant tumors such as proliferation, metastasis, invasion, and angiogenesis, resulting in the suppression of the NF-κB/IL-6/JAK2/STAT3 signaling pathway in breast cancers [62].